260 related articles for article (PubMed ID: 3295122)
1. A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1. Clinical effects.
Milligan NM; Newcombe R; Compston DA
J Neurol Neurosurg Psychiatry; 1987 May; 50(5):511-6. PubMed ID: 3295122
[TBL] [Abstract][Full Text] [Related]
2. Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ; Figgitt DP
CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
[TBL] [Abstract][Full Text] [Related]
3. Methylprednisolone in multiple sclerosis: a comparison of oral with intravenous therapy at equivalent high dose.
Alam SM; Kyriakides T; Lawden M; Newman PK
J Neurol Neurosurg Psychiatry; 1993 Nov; 56(11):1219-20. PubMed ID: 8229035
[TBL] [Abstract][Full Text] [Related]
4. Double-blind, randomized, placebo-controlled study of oral, high-dose methylprednisolone in attacks of MS.
Sellebjerg F; Frederiksen JL; Nielsen PM; Olesen J
Neurology; 1998 Aug; 51(2):529-34. PubMed ID: 9710030
[TBL] [Abstract][Full Text] [Related]
5. A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 2. Laboratory results.
Compston DA; Milligan NM; Hughes PJ; Gibbs J; McBroom V; Morgan BP; Campbell AK
J Neurol Neurosurg Psychiatry; 1987 May; 50(5):517-22. PubMed ID: 2953865
[TBL] [Abstract][Full Text] [Related]
6. Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP): a randomised, controlled, double-blind, non-inferiority trial.
Le Page E; Veillard D; Laplaud DA; Hamonic S; Wardi R; Lebrun C; Zagnoli F; Wiertlewski S; Deburghgraeve V; Coustans M; Edan G; ;
Lancet; 2015 Sep; 386(9997):974-81. PubMed ID: 26135706
[TBL] [Abstract][Full Text] [Related]
7. Double-blind randomized trial of ACTH versus dexamethasone versus methylprednisolone in multiple sclerosis bouts. Clinical, cerebrospinal fluid and neurophysiological results.
Milanese C; La Mantia L; Salmaggi A; Campi A; Eoli M; Scaioli V; Nespolo A; Corridori F
Eur Neurol; 1989; 29(1):10-4. PubMed ID: 2540005
[TBL] [Abstract][Full Text] [Related]
8. High-dose intravenous methylprednisolone in the treatment of multiple sclerosis: clinical-immunologic correlations.
Durelli L; Cocito D; Riccio A; Barile C; Bergamasco B; Baggio GF; Perla F; Delsedime M; Gusmaroli G; Bergamini L
Neurology; 1986 Feb; 36(2):238-43. PubMed ID: 3511404
[TBL] [Abstract][Full Text] [Related]
9. Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial.
Ravnborg M; Sørensen PS; Andersson M; Celius EG; Jongen PJ; Elovaara I; Bartholomé E; Constantinescu CS; Beer K; Garde E; Sperling B
Lancet Neurol; 2010 Jul; 9(7):672-80. PubMed ID: 20542736
[TBL] [Abstract][Full Text] [Related]
10. Double-blind, placebo-controlled, randomized, crossover trial of high-dose methylprednisolone in patients with chronic progressive form of multiple sclerosis.
Cazzato G; Mesiano T; Antonello R; Monti F; Carraro N; Torre P; Bosco A; Cargnelutti D
Eur Neurol; 1995; 35(4):193-8. PubMed ID: 7671978
[TBL] [Abstract][Full Text] [Related]
11. [High dose methylprednisolone therapy in patients with multiple sclerosis].
Zakrzewska-Pniewska BZ
Neurol Neurochir Pol; 1993; 27(3):313-9. PubMed ID: 8232731
[TBL] [Abstract][Full Text] [Related]
12. Evoked potentials predict the clinical changes in a multiple sclerosis drug study.
Nuwer MR; Packwood JW; Myers LW; Ellison GW
Neurology; 1987 Nov; 37(11):1754-61. PubMed ID: 3313101
[TBL] [Abstract][Full Text] [Related]
13. A randomized clinical trial of oral versus intravenous methylprednisolone for relapse of MS.
Ramo-Tello C; Grau-López L; Tintoré M; Rovira A; Ramió i Torrenta L; Brieva L; Cano A; Carmona O; Saiz A; Torres F; Giner P; Nos C; Massuet A; Montalbán X; Martínez-Cáceres E; Costa J
Mult Scler; 2014 May; 20(6):717-25. PubMed ID: 24144876
[TBL] [Abstract][Full Text] [Related]
14. NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial.
Sorensen PS; Mellgren SI; Svenningsson A; Elovaara I; Frederiksen JL; Beiske AG; Myhr KM; Søgaard LV; Olsen IC; Sandberg-Wollheim M
Lancet Neurol; 2009 Jun; 8(6):519-29. PubMed ID: 19409854
[TBL] [Abstract][Full Text] [Related]
15. Intravenous methylprednisolone for multiple sclerosis in relapse.
Barnes MP; Bateman DE; Cleland PG; Dick DJ; Walls TJ; Newman PK; Saunders M; Tilley PJ
J Neurol Neurosurg Psychiatry; 1985 Feb; 48(2):157-9. PubMed ID: 2984332
[TBL] [Abstract][Full Text] [Related]
16. Similar biological effect of high-dose oral versus intravenous methylprednisolone in multiple sclerosis relapses.
Grau-López L; Teniente-Serra A; Tintoré M; Rovira A; Ramió-Torrenta L; Brieva L; Saiz A; Cano A; Carmona O; Hervás JV; Martínez-Cáceres EM; Ramo-Tello C
Mult Scler; 2015 Apr; 21(5):646-50. PubMed ID: 25145693
[TBL] [Abstract][Full Text] [Related]
17. Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis.
Barnes D; Hughes RA; Morris RW; Wade-Jones O; Brown P; Britton T; Francis DA; Perkin GD; Rudge P; Swash M; Katifi H; Farmer S; Frankel J
Lancet; 1997 Mar; 349(9056):902-6. PubMed ID: 9093250
[TBL] [Abstract][Full Text] [Related]
18. A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis.
Hoogstraten MC; Minderhoud JM
J Neurol Neurosurg Psychiatry; 1988 Apr; 51(4):597-8. PubMed ID: 3288718
[No Abstract] [Full Text] [Related]
19. Management of worsening multiple sclerosis with mitoxantrone: a review.
Fox EJ
Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
[TBL] [Abstract][Full Text] [Related]
20. A placebo-controlled, randomized, double-masked, variable dosage, clinical trial of azathioprine with and without methylprednisolone in multiple sclerosis.
Ellison GW; Myers LW; Mickey MR; Graves MC; Tourtellotte WW; Syndulko K; Holevoet-Howson MI; Lerner CD; Frane MV; Pettler-Jennings P
Neurology; 1989 Aug; 39(8):1018-26. PubMed ID: 2668784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
